The estimated Net Worth of Mitchell H. Finer is at least $128 Thousand dollars as of 1 June 2015. Dr Finer owns over 15,000 units of Oncorus stock worth over $1,808 and over the last 11 years he sold ONCR stock worth over $0. In addition, he makes $126,648 as Co-Founder & Exec. Chairman at Oncorus.
Dr has made over 16 trades of the Oncorus stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of ONCR stock worth $367,050 on 1 June 2015.
The largest trade he's ever made was exercising 34,518 units of Oncorus stock on 8 October 2014 worth over $72,143. On average, Dr trades about 11,936 units every 23 days since 2013. As of 1 June 2015 he still owns at least 15,000 units of Oncorus stock.
You can see the complete history of Dr Finer stock trades at the bottom of the page.
Dr. Mitchell H. Finer is the Co-Founder & Exec. Chairman at Oncorus.
As the Co-Founder & Exec. Chairman of Oncorus, the total compensation of Dr Finer at Oncorus is $126,648. There are 5 executives at Oncorus getting paid more, with Stephen W. Harbin having the highest compensation of $815,088.
Dr Finer is 61, he's been the Co-Founder & Exec. Chairman of Oncorus since . There are 2 older and 6 younger executives at Oncorus. The oldest executive at Oncorus, Inc. is Dr. Mitchell H. Finer Ph.D., 62, who is the Co-Founder & Non-Exec. Chairman.
Mitchell's mailing address filed with the SEC is C/O ONCORUS, INC., 50 HAMPSHIRE STREET, SUITE 401, CAMBRIDGE, MA, 02139.
Over the last 4 years, insiders at Oncorus have traded over $1,276,271 worth of Oncorus stock and bought 2,354,001 units worth $35,555,648 . The most active insiders traders include Ansbert Gadicke, Luke Evnin, and James E Deerfield Mgmt Hif,.... On average, Oncorus executives and independent directors trade stock every 34 days with the average trade being worth of $15,538. The most recent stock trade was executed by James E Deerfield Mgmt Hif,... on 28 December 2022, trading 336,235 units of ONCR stock currently worth $87,421.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Oncorus executives and other stock owners filed with the SEC include: